First RayStation® order in China

Read original

RaySearch Laboratories AB received regulatory market approval in July by the Chinese regulatory agency CFDA for RaySearch’s treatment planning system RayStation® and today RaySearch received the first RayStation® order on the Chinese market. The order was received from Ganzhou People’s Hospital in Ganzhou, Jiangxi Province, China.

Ganzhou People’s Hospital will use RayStation® for treatment planning of both conventional treatments and IMRT. The order also includes advanced tools enabling a more efficient treatment planning process, such as Multi-Criteria Optimization (MCO). This highly intuitive tool lets the clinician evaluate the impact of changing different treatment priorities in real-time, which has a large potential to speed up the time-consuming treatment planning optimization process.

“RayStation® helps us solve complicated tumor cases and increase the speed of the physicists’ tasks. Especially MCO is an excellent module that speeds up the clinical process”, says Director Deng from Ganzhou People’s Hospital.

Frank Qian, President of the regional distributor Beijing KangLiDa Trading Corp. that is responsible for marketing, sales and service of RayStation® on the Chinese market, adds: ”The cancer treatment technology in China needs to evolve fast and RayStation® contains a lot of unique advanced tools that meet the technology development needs on the Chinese market. With its excellent development team I believe RaySearch will remain in the forefront in the field of radiation treatment planning.”

“China is one of the largest radiation therapy markets in the world today and it has perhaps the largest growth potential of all markets. This means that we are of course happy to receive our first order so quickly after securing regulatory approval. Kang Li Da is in the final stages of negotiations with several other clinics as well so we have high hopes for this market for the remainder of the year”, says Johan Löf, CEO of RaySearch.

    
About RayStation®

RayStation® integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.

About RaySearch
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch’s products are mainly sold through license agreements with leading partners such as Philips, Nucletron, IBA, Varian, Accuray and Brainlab. To date, 15 products have been launched through partners and RaySearch’s software is used at over 2,000 clinics in more than 30 countries. In addition, RaySearch offers the proprietary treatment planning system RayStation® directly to clinics. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.

For more information about RaySearch, visit www.raysearchlabs.com

For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB
Telephone: +46 (0)8-545 061 30
johan.lof@raysearchlabs.com

About Us

RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation® treatment planning system to clinics all over the world. In addition, RaySearch’s products are distributed through licensing agreements with leading medical technology companies such as Philips, Nucletron, IBA, Varian and Brainlab. To date, 15 products have been launched via partners and RaySearch’s software is used by over 2,500 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the company is listed in the Small Cap segment on Nasdaq Stockholm.

Subscribe

Documents & Links